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Neuregulin-1 binds to ErbB3 and ErbB4 and regulates cancer proliferation and differentiation.
Neuregulin-1 had been suggested to also react with ErbB2, but this argument becomes controversial. Here,
we re-evaluated the cellular responses and ErbB2 interaction of neuregulin-1 in ErbB2 overexpressing cell
lines. In a competitive ligand-binding assay, we detected significant replacement of [35S]-labeled
neuregulin-1 with nanomolar ranges of cold neuregulin-1 in L929 cells expressing ErbB2 alone and SKOV3
cells carrying sulf-1 cDNA but not in these parental cells. The concentration of neuregulin-1 significantly
decreased thymidine incorporation and phosphorylation of ErbB2 (Tyr877, Tyr1396, and Tyr1121) in
ErbB2-overexpressing cancer cells as well as in L929 cells expressing ErbB2. A crosslinking assay ascertained
the presence of neuregulin-1 immunoreactivity in the ErbB2 immune complexes of L929 expressing ErbB2
alone. These results suggest that the higher concentrations of neuregulin-1 exert an anti-oncogenic activity
to attenuate ErbB2 auto-phosphorylation potentially through its low-affinity interaction with ErbB2.
A
receptor molecule for neuregulin-1 (neu-differentiation factor or heregulin) was initially suggested to be
not only ErbB3 and ErbB4 but also ErbB2 (Her2, Neu)1,2. The following studies demonstrate that the high
affinity interaction of ErbB2 with neuregulin-1 involves ErbB3 hetrodimerization and tone down the
argument for the direct ErbB22neuregulin-1 interaction3–6. ErbB2 is often overexpressed with or without gene
amplification in various cancer cells, such as mammary cancer cells and ovarian cancer cells7–10. ErbB2 over-
expression results in ligand-independent self-dimerization and subsequent auto-phosphorylation, leading to
downstream signaling linked to cell proliferation and migration. Thus, the extent of ErbB2 overexpression in
cancer cells is sometimes correlated with malignancy and/or a poor prognosis11,12. Recently, various anti-cancer
drugs that target ErbB2 have been developed, including anti-ErbB2 antibodies that inhibit ErbB2 self-dimeriza-
tion or induce its down regulation13,14. In this regard, ErbB2 auto-phosphorylation play key roles in the prolif-
eration of the cancer cell lines overexpressing ErbB215–17.
After two initial reports demonstrated an interaction between neuregulin-1 and ErbB2, subsequent studies
questioned the receptor function of ErbB2. There are two major reasons why ErbB2 cannot function as a high-
affinity receptor for neuregulin-1. First, many ovarian cancer cell lines that express high levels of ErbB2 do not
exhibit an increase in ErbB2 phosphorylation in response to neuregulin-13. Secondly, [125I]-labeled neuregulin-1
exhibits a low or no binding affinity for these cells4,18. However, other studies still indicate that the direct
interaction between ErbB2 and neuregulin-1 might be real despite the weak affinity3,19. In addition, subsequent
studies further increase the complexity of this argument; there are positive and negative regulators for ErbB
receptor function and subcellular localization. For example, sulfatase-1 (Sulf-1), which removes O-sulfate groups
of heparin or heparan sulfate proteoglycans, significantly influence the molecular interaction of neuregulin-1
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with ErbB receptors20,21. Of note, approximately 70% of ovarian can-
cer cells lost the expression of sulf-1 and exhibit higher grades of
malignancy often with ErbB2 overexpression21,22. With this respect,
the affinity and biological role of the neuregulin-1–ErbB2 receptor
interaction remains to be controversial and needs to be re-evaluated.
To clarify this issue, we carefully assessed the molecular response
of an ovarian cancer line, SKOV3, and a breast cancer line, BT-474, to
neuregulin-1, both of which highly express ErbB2.We also used L929
mouse fibroblasts that lack the expression of ErbBs or those trans-
fected with erbB2 cDNA.Molecular interactions of ErbB2 with neur-
egulin-1 were examined with novel procedures for ligand labeling
and immunoprecipitation. In particular, we manipulated the
expression of heparan sulfatase-1 in the ovarian cancer cells as the
O-sulfate structures markedly alter receptor interactions of the hep-
arin-binding growth factors such as neuregulin-120,21. With the
obtained results, we discuss the involvement of ErbB2 in neuregu-
lin-1 signaling and functions.
Results
Expression of ErbB1-4 proteins in L929, SKOV3, and BT-474
cells. The primary amino acid sequences of the ErbB molecular
family members share high structural homology and are often
cross-recognized by antibodies raised against different subtypes. As
the previous reports demonstrate that mouse fibroblast L929 cells
have no binding to neuregulin-1 and harbor the limited expression of
ErbB2, we employed parental L929 cells as a negative control and
transfected these cells with erbB1, B2, B3 or B4 cDNA expression
vectors as positive controls23,24. We examined and confirmed endo-
genous ErbB1-4 expression in the cell lines (i.e., L929, SKOV3,
SKBR3 and BT-474 cells) used in the present study (Fig. 1a). Al-
though L929 cells expressed trace amounts of ErbB2, these cells
lacked detectable levels of ErbB1, ErbB3 and ErbB4 as described
previously23–25. SKOV3 cells expressed high levels of ErbB2 and
ErbB1 and low levels of ErbB4, whereas BT-474 expressed high
levels of ErbB2 and low levels of ErbB3 and ErbB1 when we com-
pared those with ErbB1-4 levels in transfected L929 cells.
Although these cell lines contained ErbB2 proteins, they could be
nonfunctional if they are not located at the cell surface.We examined
the cell surface expression of ErbB2 in the above cell lines by surface
biotinylation (Fig. 1b). Except for the parental L929, there were sig-
nificant surface levels of the ErbB2 protein in all cell lines, which
appeared to be correlated with the total ErbB2 levels.
To mimic the ErbB2-overexpression state of the cancer cells in
L929 cells, we established the L929 cell line that stably carries erbB2
cDNA through neomycin selection. By transiently transfecting an
erbB2-expression vector, we further boosted ErbB2 expression in this
cell line and used these ErbB2-overexpressing L929 cells (referred to
as ErbB2-L929 hereafter) in the following experiments. Again, we
confirmed that the transfection of erbB2 cDNA and G418 selection
did not induce the expression of ErbB3 and ErbB4 in ErbB2-L929
cells (Supplemental Figure S1).
Responses of ErbB2-overexpressing cells to neuregulin-1. The
ovarian cancer cell line, SKOV3, is reported not to have a high
affinity for neuregulin-12,3. We re-examined the cellular responses
of SKOV3 cells to relatively high concentrations of neuregulin-1,
monitoring their cell proliferation and competitive binding acti-
vity. The rates of cell proliferation were measured using [3H]
thymidine incorporation in the presence or absence of 10 nM and
40 nM type I neuregulin-1 (a soluble form comprising the extra-
cellular domain; ECD) as well as with or without the transfection
of sulf-1 (sulfatase 1) cDNA (Fig. 2a). As blood serum contains high
levels of neuregulin-1, SKOV3 cells were extensively washed prior to
the assay26. The concentration of 10 nM neuregulin-1 had no
apparent influence on thymidine incorporation, whereas 40 nM
neuregulin-1 significantly decreased incorporation compared with
untreated controls. SKOV3 cells lack the enzyme Sulf-1, which
selectively removes the 6-O-sulfate group from heparan sulfate27
and regulates neuregulin-1 binding to ErbB receptors20. We also
tested the effect of Sulf-1 expression on the thymidine incorpor-
ation of SKOV3 cells. The transfection of sulf-1 cDNA further
increased the response to neuregulin-1. In addition, we assessed
the effects of 40 nM neuregulin-1 on BT-474 cells, ErbB2-L929
cells, and parental L929 cells (Fig. 2c, d). We observed a similar
anti-proliferative activity of neuregulin-1 in BT-474 cells and
ErbB2-L929 cells, but not in parental L929 cells.
We recently developed a simple method that enables us to syn-
thesize and label authentic neuregulin-1 with the radioisotope [35S]
methionine28. This procedure does not involve additional chemical
modification, such as iodination and/or oxidization of the target
protein, we can avoid the structural hindrance of the additional atom
in the receptor-binding assay. In fact, we found that the iodination of
neuregulin-1 proteins (i.e., NRG1-ECD and an EGF domain peptide
of neuregulin-1; eNRG1) significantly reduced their biological activ-
ity (Supplemental Figure S2). In the present study, therefore, we
prepared a [35S]-labeled ligand of neuregulin-1 by this in vitro trans-
lation system.We performed the competitive ligand-binding assay in
Figure 1 | Cellular and surface expression of ErbB1-4 in L929 and cancer
cells (a) Proteins were extracted from untransfected L929 cells, L929 cells
transfected with erbB1-4 cDNA, or BT-474, SKBR3, and SKOV3 cancer
cells and were probed with antibodies raised against ErbB1, ErbB2, ErbB3,
ErbB4, andG6PDH (control). (b) Living cells were exposed to Sulfo-NHS-
biotin to label surface proteins. Biotinylated proteins were subjected to
Western blotting for ErbB2. Arrowheads marks the position of 175 kDa
molecular marker and 3 represents the non-specific immunoreactivity
that commonly appears in many types of cells.
www.nature.com/scientificreports
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SKOV3 cells with this [35S]-labeled ligand (Fig. 2b). As reported
previously, there was no significant replacement of [35S]-labeled
neuregulin-1 in SKOV3 cells3. Again, we examined the effects of
sulf-1 cDNA transfection on neuregulin-1 binding to this cell line.
When the sulf-1 gene was transduced into these cells, there was a
significant replacement of [35S]-labeled neuregulin-1 with 40 nM of
cold neuregulin-1. The absence of Sulf-1 protein expression in the
parental SKOV3 cells as well as its presence after transfection was
confirmed by Western blotting (Supplemental Figure S3).
ErbB2 dephosphorylation following neuregulin-1 challenge. The
above results suggest the biological implication of ErbB2 signaling in
the anti-proliferative responses to neuregulin-1. We examined time-
dependent alterations in ErbB2 phosphorylation (Tyr877, Tyr1139,
and Tyr1196) of SKOV3 cells following neuregulin-1 challenge
(Fig. 3a). Western blotting with anti-phospho ErbB2 antibodies
suggested that exposing SKOV3 cells to 40 nM neuregulin-1
rapidly decreased the phosphorylation levels of ErbB2 at Tyr877,
Tyr1139, and Tyr1196. Statistical analyses revealed that the
decrease in Tyr1196 phosphorylation was statistically significant
and continued at least for 3 h. In contrast, there were no apparent
alterations in the total protein levels of ErbB2 and b-actin.
Similarly, we examined time-dependent ErbB2 dephosphoryla-
tion in another ErbB2-overexpressing cell line, BT-474 (Fig. 3b).
BT-474 cells exhibited anti-proliferative responses to neuregulin-1
(see Fig. 2) whereas these cells also express ErbB3 whose signaling
promotes cell proliferation29,30. Neuregulin-1 treatment indeed
elevated ErbB3 phosphorylation in BT-474 cells. In parallel,
neuregulin-1 challenge triggered the rapid dephosphorylation of
ErbB2 at Tyr877, Tyr1139, and Tyr1196 as was seen in SKOV3
cells. In contrast to the effects on SKOV3, ErbB2 dephosphoryla-
tion at Tyr1196 did not continue more than 180 min, however.
It was not evident that the observed dephosphorylation of ErbB2
might involve the interaction of neuregulin-1 with ErbB4 and ErbB3
receptors expressed by SKOV3 and BT-474 cells, respectively. We
examined ErbB2 phosphorylation in ErbB2-L929 cells (Fig. 3c).
When we challenged ErbB2-L929 cells with neuregulin-1, we found
similar rapid decreases in ErbB2 phosphorylation at Tyr877, Tyr
1139, and Tyr 1196. Statistical analysis of Tyr 1196 phosphorylation
verified that there was a significant reduction in ErbB2 tyrosine
phosphorylation. In comparison with the duration of the depho-
sphorylation in SKOV3 and BT-474 cells, the ErbB2 dephosphoryla-
tion had a shorter duration and did not continue more than 20 min
in ErbB2-L929 cells.
Figure 3 | Neuregulin-dependent and time-dependent decreases in ErbB2
phosphorylation (a) SKOV3 cells that had been transfected with sulf-1
cDNA and subjected to serum starvation were challenged with 40 nM
neuregulin-1. Time-dependent alterations in ErbB2 phosphorylation at
Tyr877, Tyr1139, or Try1196 as well as in authentic ErbB2 levels were
examined byWestern blotting. (b) Gel loading was controlled with b-actin
levels. Changes in ErbB2 and ErbB3 phosphorylation were also assessed in
BT-474. (c) Changes in ErbB2 phosphorylation were similarly assessed in
ErbB2-L929 cells. *p , 0.05, **p, 0.01, ***p, 0.001, compared to the
values of 0 time point (n 5 3).
Figure 2 | Effects of neuregulin-1 on cell proliferation and binding to [35S]-
labeled neuregulin-1 (a) SKOV3 cells that were transfected with sulf-1
cDNA were serum-starved and then challenged with neuregulin-1 (10 nM
or 40 nM).% ratios of changes in [3H] thymidine incorporation were
calculated compared to that of untreated and mock-transfected SKOV3
cells. (b) Binding of [35S]-labeled neuregulin-1 to SKOV3 cells was
measured in the presence or absence of 40 nM cold neuregulin-1. (c) The
effects of 40 nM neuregulin-1 on [3H] thymidine incorporation in BT-474
cells were assessed. (d) [3H] thymidine incorporation in parental L929 cells
or ErbB2-L929 cells was determined. *p, 0.05, **p, 0.01, ***p, 0.001,
compared to control cells.
www.nature.com/scientificreports
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Competitive binding of neuregulin-1 to L929 cells overexpressing
ErbB2. Does ErbB2 dephosphorylation stem from the molecular
interaction or association of ErbB2 with neuregulin-1? To
challenge this question, ErbB2-L929 cells as well as parental L929
cells were examined in a competitive ligand-binding assay (Fig. 4).
The total binding of [35S]-labeled neuregulin-1 to ErbB2-L929 cells
was gradually diminished with increasing concentrations of cold
neuregulin-1. IC50 of the neuregulin-1 binding was approximately
10 nM. In contrast, parental L929 cells exhibited reduced total
binding to [35S]-labeled neuregulin-1 and failed to show any
significant replacement with 10 nM cold neuregulin-1. This result
agrees with the report that the cytotoxicity of toxin-conjugated
neuregulin-1 is undetectable in parental L929 cells24.
Since we did not modify the chemical structure of the ligand, [35S]-
labeled neuregulin-1 should have the same affinity to ErbB receptors
as authentic neuregulin-1. Thus we can assume that Ki is equal to Kd
in the Cheng-Prusoff equation. According to this equation, we estim-
ate that Kd of neuregulin-1 binding was ,12 nM or less with the
given IC50 (approximately 10 nM) and the concentration of the
tracer (i.e. 1.9 nM) in this assay.
Appearance of the ErbB2 complexes crosslinked to cold neuregulin-
1. Using chemical crosslinking of cold neuregulin-1 to ErbB2, we
attempted to visualize the receptor complexes of neuregulin-1 and
ErbB2 using Western blotting with the anti-neuregulin-1 antibody.
In our preliminary experiment, we first tested the immunopre-
cipitation performance of anti-ErbB2 antibodies. SKBR3 cells, which
express both ErbB2 and ErbB3, were exposed to a chemical
crosslinker. Then we attempted to immunoprecipitate the ErbB2
complexes with four distinct anti-ErbB2 antibodies using the
conventional immunoprecipitation procedure of the non-denatured
condition (Supplemental Figure S4). However, all the anti-ErbB2
antibodies failed to immunoprecipitate the ErbB2 complexes when
the cells were treated with the chemical crosslinker, even though all
these antibodies were able to immunoprecipiate authentic ErbB2
protein (Supplemental Figure S4). These results suggest that the
amine-reactive chemical crosslinker masks the epitopes for the anti-
ErbB2 antibodies in the non-denatured condition.
Alternatively, we took the SDS-denatured condition for ErbB2
extraction and then immunoprecipitated the ErbB2 complexes
(Fig. 5a, b). In the ErbB2 immune complexes as well as in the total
cell lysate, we detected the neuregulin-1-like immunoreactivities
slightly below the 175 kDa maker as well as above the 235 kDa
marker (lanes 2, 3 in a) whereas there were no apparent neuregu-
lin-1-immunoreactive bands in the absence of neuregulin-1 (lane 1
in A). In contrast, the neuregulin-1-like immunoreactivity in the
complexes disappearedwhen the chemical crosslinkage was digested,
suggesting that these immunoreactivities indeed represent the
molecular complexes containing neuregulin-1. When we probed
the membrane with the anti-ErbB2 antibody, there were ErbB2
immunoreactivities in the immunoprecipitates (lanes 3 in b).
However, the molecular size of the immunoreactivities was smaller
than the authentic size of ErbB2. The digestion of the crosslinkers
uncovered the masked ErbB2 epitopes and re-emerged the ErbB2
immunoreactivity at the authentic size (lane 4 in b). We found sim-
ilar gel mobility shift of the ErbB2 immunoreactivity when BT474
cells were treated with a chemical crosslinker (data not shown). The
phenomenon agrees with the fact that the intramolecular crosslink-
age is known to fold and pack a bulky polypeptide chain and
increases its gel mobility31.
Thus, we speculate that that the mobility of ErbB2 was increased
by chemical crosslinkage and shifted to a lower molecular range.
These results suggest that the high concentration of neuregulin-1
can associate with ErbB2.
Discussion
In the present investigation, we demonstrated the biological actions
of neuregulin-1 in distinct cell lines harboring high ErbB2 express-
ion. Treating with 40 nM neuregulin-1 resulted in a significant
decrease in thymidine incorporation as well as in ErbB2 phosphor-
ylation in cancer cells with erbB2 amplification. The lower dose of
Figure 4 | Competitive binding assay of [35S]-labeled neuregulin-1 to
ErbB2-overexpressing L929 cells. The tracer of neuregulin-1 was
synthesized using the rabbit reticulocyte lysate system in the presence of
[35S]-methionine. [35S]-labeled neuregulin-1 (1.7 kBq, 1.9 nM) was
incubated in the presence of various concentrations of cold neuregulin-1
(0–40 nM). The ratios relative to the maximum binding with no
competitor (100%) were determined in triplicate (n 5 3). Data represent
mean 6 SE. Note; the total binding of the tracer was decreased to 54.3 6
3.1% in parental L929 cells that were not exposed to cold neuregulin-1. The
putative background binding found in parental L929 cells was not
compensated as parental L929 cells express a low level of ErbB2.
Figure 5 | A crosslink study of neuregulin-1 in ErbB2-overexpressing
L929 cells ErbB2-L929 cells were incubated with or without 40 nM cold
neuregulin-1 and then exposed to the amine-reactive crosslinker
sulfo-EGS. Total cell lysates (Total) and ErbB2 immunoprecipites (IP)
were subjected to Western blotting with the anti-neuregulin-1 antibody
(a) or anti-ErbB2 antibody (b). Prior to the electrophoresis, half of the
immune complexes were treated with 1 M hydroxylamine to cleave the
crosslinkage (lane 4). Arrowheads indicate the positions of molecular
weight markers (kDa) Note; the cleavage of the crosslinker conversely
elevated ErbB2 immunoreactivity (lanes 4 in b).
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 3 : 1402 | DOI: 10.1038/srep01402 4
10 nM neuregulin-1 did not significantly affect thymidine incorp-
oration of SKOV3 cells, however. The anti-proliferative reaction was
also found in SKOV3, BT-474 and L929 cells overexpressing ErbB2,
but not in the parental L929 cells. The dose-dependency of neuregu-
lin-1 in thymidine incorporation roughly agrees with the profile of
the competitive ligand-binding assay; nano molar concentrations of
neuregulin-1 were able to replace the cell binding of [35S]-labeled
neuregulin-1. The competitive interaction of neuregulin-1 in
SKOV3 cells required additional expression of Sulf-1, however.
The low-affinity interaction between neuregulin-1 and ErbB2 was
ascertained by the crosslink study as well; there was neuregulin-1
immunoreactivity in the ErbB2 immune complexes in ErbB2-L929
cells. Therefore, the present findings suggest that neuregulin-1 chal-
lenge exerts anti-proliferative effects, which presumably involve the
direct or indirect interaction of neuregulin-1 with ErbB2. However,
we confirmed that the biological interaction of neuregulin-1 is sig-
nificantly influenced by the structures of heparan sulfate moiety on
cell surfaces of ErbB2-overexpressing cells20.
There were significant levels of basal tyrosine phosphorylation of
the ErbB2 kinase domain in ErbB2-overexpressing cell lines. The
high level of ErbB2 phosphorylation in L929 cells was achieved by
both transient and permanent transfection of erbB2 cDNA. ErbB2-
overexpressing L929 cells responded to neuregulin-1 and exhibited a
consistent decrease in ErbB2 phosphorylation at multiple tyrosine
residues. In contrast, the parental L929 cells exhibited almost no
response to neuregulin-1 in the cell proliferation test and competitive
binding assay. There results support the previous findings that the
parental L929 cells express a limited level of ErbB2 but no detectable
levels of authentic receptors for neuregulin-124,25. With the given
proliferative action of ErbB2 auto-phosphorylation7,8,13,14, therefore,
we assume that the neuregulin-1-triggered ErbB2 dephosphorylation
plays a key role in the attenuation of the cell proliferation observed.
However, these findings and/or the data explanations appear to be
contradictory against the previous report that the transfection of
erbB2 cDNA to L929 cells fail to induce their interaction with
[125I]-labeled neuregulin-1 or alter neuregulin-1-triggered ErbB2
phosphorylation3. The differences from the present results might
stem from the fact that serum contains so high concentrations of
neuregulin-1 (i.e. ,200 pM for human serum) that serum-supple-
mented culture media can perturb these assays27. In fact, extensive
cell wash or starvation prior to these assays was essential in the
present study. Alternatively, it might be illustrated by the fact that
the iodination of neuregulin-1 limits its interaction to ErbB2 receptors
and perturbs the ligand-binding assay (see Supplemental Figure S2).
Still there is another argument against our conclusion; ErbB4
signaling has been suggested to underlie the anti-proliferative action
of neuregulin-1 in some cancer cell lines and might contribute to the
observed anti-proliferative phenomena. This scenario might poten-
tially illustrate the results from the SKOV3 cells harboring a low level
of ErbB4. However, the lack of ErbB4 expression in ErbB2-expres-
sing L929 and BT-474 limits this explanation32,33. Alternatively, the
anti-proliferative action of neuregulin-1 might be ascribed to ErbB2
down-regulation34,35. However, we did not find decreases in total
ErbB2 immunoreactivity in SKOV3, BT-474, and ErbB2-L929 cells
following acute neuregulin-1 challenge when we used fresh blotting
membranes for ErbB2 detection (see Material and Methods).
Accordingly, we assume that the neuregulin-1-depedent decrease
in the proliferation of SKOV3, BT-474, and ErbB2-L929 cells
involves attenuated ErbB2 auto-phosphorylation.
There are many novel molecules identified that regulate homo
or hetero dimerization of ErbB2 and potentially modify direct
and indirect interaction with neuregulin-1 as well; erbin, decorin,
and RALT (receptor-associated late transducer)36. Erbin binds to
the carboxyl terminal of ErbB2 and anchors ErbB2 to cytoskeletal
networks to regulate its dimerization and protein stability37–39. RALT
also interacts with the tyrosine kinase domain of ErbB2 and promote
its lysosomal degradation40–42, although Anastasi et al.41 report the
limited expression of RALT in BT-474 and SKBR3. Decorin is sug-
gested to attenuate ErbB2 phosphorylation but involving ErbB4
interaction43. These findings indicate the possibility that the homo-
meric interaction of ErbB2 or its autophosphorylation can be mark-
edly influenced by these ErbB2-interacting molecules. Thus, the
involvement of these ErbB2-interacting molecules might illustrate
the previous controversy of the anti-proliferative action of neuregu-
lin-1 among literatures32–35.
The present immunoprecipitation results provide circumstantial
evidence that ErbB2 functions as a low-affinity receptor for neure-
gulin-1. The given epitope masking of ErbB2 by chemical crosslink-
age made our experiments difficult. However, this argument is
consistent with a previous study using the ligand-binding assay in
SKOV3 cells. [125I]-labeled type 1 neuregulin-1 is indeed replaced
with 40 nM cold neuregulin-13. The surface plasmon technique
demonstrates the direct interaction between ErbB2 and neuregu-
lin-1; immobilized neuregulin-1 on a solid phase bound to the
recombinant extracellular domain of ErbB2 with a calculated dis-
sociation constant (Kd) of 850 nM19, which is one digit larger than
the present value, however. The variation in Kd is presumably
ascribed to the difference of the experimental procedures; the in vitro
solid phase system vs. the natural cell-based binding system. In the
ErbB2 immunoprecipiates, we additionally detected the neuregulin-
1-like immunoreactivities that carried much larger molecular sizes
(.250 kDa). In this context, we do not rule out that the observed
dephosphorylation of ErbB2 or the attenuation of cell proliferation
may involve unknown receptors for neuregulin-1, which might form
the molecular complexes with ErbB244. For example, cell-ubiquitous
proteins, integrins are reported to interact directly with neuregulin-
145,46. Alternatively, ErbB2 forms the hetero-oligomer with the other
receptor tyrosine kinases as well47. Thus, several possibilities and
controversies still remain regarding themolecular nature of the neur-
egulin-1 receptor complexes found in the ErbB2-expressing cells.
However the present results, at least, suggest that neuregulin-1 trig-
gers ErbB2 dephosphorylation and the anti-proliferative action in an
ErbB2 expression-dependent manner. Thus, our present study
reveals and confirms an anti-oncogenic role of neuregulin-1 in
ErbB2-overexpressing cancer cells.
Methods
Plasmid construction. cDNA for the human type I neurergulin-1 beta3 isoform
(i.e. extracellular domain neuregulin-1; NRG1-ECD) was chemically synthesized by
GenScript USA Inc. (Piscataway, NJ, USA) and subcloned into the pET-22b(1)
plasmid (EMD Chemical Darmstadt, Germany) or pcDNA TM 3.1-TOPO TA
plasmid (Invitrogen Corporation, Carlsbad, CA,USA), both of which carry T7 and/or
cytomegalovirus promoters. cDNA for human Sulf-1 was synthesized from human
brain RNA by RT-PCR and subcloned into the pcDNA TM 3.1-TOPO TA plasmid
(Invitrogen). The expression vectors carrying human erbB1 cDNA and erbB2 cDNA
were obtained from a Riken genome bank (Wako, Saitama, Japan)48 and those for
erbB3 and erbB4 cDNAs were prepared as reported previously49.
Cell culture.We obtained cell lines, SKOV3, SKBR3, BT-474 and L929 cells, from the
American Type Culture Collection (ATCC, Manassas, VA, USA) and SKBR3 cells
fromDr. Sakamaki (Niigata University of Pharmacy and Applied Life Sciences). Cells
that overexpress ErbB2 were grown in DMEM/F12 medium (Invitrogen, Tokyo,
Japan) with 10% heat-inactivated fetal calf serum (Hyclone; Thermo Scientific,
Yokohama, Japan). These cells were subjected to experiments within six passages.
Mouse L929 cells were transfected with a human erbB2-expression vector and grown
in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 5% heat-
inactived calf serum (CS) (Invitrogen, Tokyo, Japan) for two days (see below). Some
of the cells were exposed to genestin G418 (0.4 mg/ml; Sigma-Aldrich Japan, Tokyo,
Japan) for three weeks. Cells that were resistant to G418 and thus expressed ErbB2
were cloned. The expression of ErbB2 in the erbB2 transformants was further boosted
with the transient transfection of a human erbB2-expression vector for the binding
assay or phosphorylation assay.
Cell surface biotinylation. Cells were extensively washed with Hank’s balanced salt
solution (HBSS) and incubated with 2 mM Sulfo-NHS-biotin (Pierce/Thermo
Scientific, Yokohama, Japan) at room temperature for 20 min, after which the
reaction was quenched with 50 mM Tris HCl and 10 mM ethanol amine (pH 8.0).
Cells were lysed with PIPA buffer [25 mM Tris HCl pH 7.6, 150 mM NaCl, 1%
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NP-40, 0.5% sodium deoxycholate, and 0.1% SDS] containing a protease inhibitor
cocktail (Boehringer Ingelheim Pharma Japan, Tokyo, Japan) and mixed with
streptavidin beads (Sigma-Aldrich). The biotinylated proteins that were trapped with
the beads were liberated by boiling with SDS sample buffer (see below).
Competitive binding assay. According to our method23, [35S]-methionine-labeled
neuregulin-1 (type I NRG1-ECD; 2300 dpm/fmol) was synthesized using the
reticulocyte lysate translation system (Promega). The pET-22b(1) vector (1 mg) was
directly transcribed and translated in vitro in the presence of [35S]-methionine
(740 kBq, 43500 TBq/mol; American Radiolabeled Chemical Inc., Saint Louis, MO,
USA). The incorporation of [35S] methionine into the protein fraction was estimated
using alkaline treatment followed by trichloroacetic acid precipitation. The specificity
and authenticity of translated neuregulin-1 was fully evaluated previously28.
L929 cells and SKOV3 cells during the growth phase were plated at a density of
5 3 104 cells/well in poly D-lysine-coated 48-well plates. Cells were extensively
washed with Leibovitz -15 Medium (L-15; pH 7.4; Sigma-Aldrich, Japan) containing
0.1% bovine serum albumin (immunoglobulin-free grade; Sigma-Aldrich, Japan) and
10 mMHEPES. [35S]-methionine-labeled neuregulin-1 (16.7 kBq/mL, 8900 Bq/pmol)
was mixed with 0–40 nM of a cold competitor of human recombinant neuregulin-1
(type 1 NRG1-ECD; R&D Systems, Minneapolis, MN, USA). Cells were incubated
with the tracer mixture on ice for 2 h. After washing with L-15 buffer, L929 cells were
lysed with 0.5 N NaOH. The radioactivity of the cell lysates was determined using the
Liquid Scintillation System LSC-3050 (Aloka, Tokyo, Japan).
Western blotting. Protein samples were prepared from cultured cells for Western
blot analyses. These samples were homogenized in cell lysis buffer [25 mM Tris HCl
pH 7.6, and 2% SDS] by sonication and denatured in the presence of 100 mM
dithiothreitol (Wako Chemicals, Tokyo, Japan) at 85uC for 5 min. In parallel, the
protein concentrations were determined using a micro-BCA kit (Protein Assay
Reagent; Pierce/Thermo Scientific). Typically, 20 mg of protein was subjected to
SDS-polyacrylamide gel electrophoresis and then transferred onto a nitrocellulose
membrane (Advantec, Tokyo, Japan). The membrane was probed with anti-ErbB1
(Eptomics Inc., Burlingame, CA, USA), anti-ErbB2 (Eptomics Inc.), anti-ErbB3
(Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-ErbB4 (Cell Signaling
Technology, Danvers, MA, USA), or anti-phospho ErbB2 or anti-phospho ErbB3
antibodies (Cell Signaling; Eptomics Inc.). We used fresh blotting membranes to
detect total and phosphorylated ErbB2 proteins as the conventional stripping
procedure did not allow us to reuse themembrane that had been treated with the anti-
phospho ErbB2 antibodies (data not shown). A blotting membrane was also probed
with the anti-Sulf-1 antibody (Abcam, Cambridge, UK). After extensive washing, the
immunoreactivity of the membrane was detected with a horseradish peroxidase-
conjugated anti-rabbit immunoglobulin followed by a chemiluminescence reaction
(ECL kit, GE Healthcare Japan Co., Tokyo, Japan or Immuno Star LD, Wako
Chemical, Tokyo, Japan). The intensity of an immunoreactive band, whose size
matched the authentic molecular weight, was measured by a CCD camera and an
image processing software, GENETOOLS (Syngene, Cambridge, UK). Comparable
protein loading was confirmed by Western blotting using an anti-b-actin antibody
(Merck Millipore Japan, Tokyo, Japan).
Cell proliferation assay. L929, SKOV3, and BT-474 cells were maintained at a
growth phase. Growing cells were plated at a density of 1 3 105 cells/well in 24-well
dishes that had been coated with 0.1 mg/ml poly-D-lysine hydrobromide (Sigma-
Aldrich, Japan). The cells were allowed to adhere for 20–40 h, and then starved in
serum-free DMEM medium containing 10 mM HEPES for 14-20 h. Thirty-seven
kilo Bq/ml of [3H]thymidine (Perkin Elmer, Waltham, MA, USA) and various
concentrations of recombinant neuregulin-1 (R&D Systems) were added to each well.
After 4-h incubation, the cells were washed once with HBSS and then fixed with 5%
trichloroacetic acid at 4uC for 45 min. The cells were solubilized in 0.2 ml of 0.5 N
NaOH at room temperature. One tenth of the cell lysates was mixed with 5 ml of
Ready Value scintillation fluid (Beckman Instruments, Fullerton, CA, USA) and the
radioactivity was measured using a liquid scintillation counter LSC-3050 (Aloka).
Chemical crosslinking of neuregulin-1. L929 cells expressing ErbB2 (0.5 2 1.0 3
106 cells) or SKBR3 cells were harvested or incubated with 40 nM human
recombinant neuregulin-1 (NRG1-ECD, R&D Systems) at 20uC for 15 min in HBSS.
The neuregulin-1 solution was then replaced with 2.0 mM of the crosslinker
bis(sulfosuccinimidyl) substrate (BS3; Pierce/Thermo Scientific) or ethylene glycol
bis-sulfosuccinimidylsuccinate (Sulfo-EGS; Pierce/Thermo Scientific) and then
quenched with 50 mM Tris HCl and 10 mM ethanol amine (pH 8.0). The cells were
lysed with PIPA buffer and then immunoprecipitated for ErbB2. Alternatively, cell
lysates were prepared by homogenizing cells with a 1% SDS solution at 70uC and then
incubated with 0.5M potassium chloride in the presence of 1% NP-40 and a protease
inhibitor cocktail (Boehringer Ingelheim) to replace the detergent. The ErbB2
complexes in PIPA buffer were treated with anti-ErbB2 antibodies (C-18; Santa Cruz
Biotechnology, Ab-3; Merck Millipore Japan, trastuzumab; Roche, Swiss, or
polyclonal 06-562; Merck Millipore Japan) for overnight and precipitated with
Protein-G Sepharose (GE Healthcare, Tokyo, Japan). Alternatively, the complexes in
the denaturing condition were immunoprecipitated with the ErbB2 antibody used in
Western blotting (Eptomics Inc.).
The total cell lysates and the immunoprecipitates were separated using 6%
SDS-PAGE and probed with an anti-neuregulin-1 antibody (Santa Cruz
Biotechnology) or with an anti-ErbB2 antibody (Eptomics Inc.). To control the
efficacy of the ErbB2 immunoprecipitation, some cells were not exposed to the
crosslinker and directly subjected to Western blotting for ErbB2. To cleave the
chemical crosslinkage of Sulfo-EGS, ErbB2 immunoprecipitates in the Protein-G
Sepharose beads were treated with 1 M hydroxylamine (pH 8.5), prior to gel loading.
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